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ABSTRACT 
Immunostimulatory adjuvants are substances added to vaccines to promote and 
direct a robust Th1, Th2, or Th17 immune response. Murine Th17 cells are produced and 
differentiated from naïve T cells in the presence of transforming growth factor (TGF)-β 
and interleukin (IL)-6 and once differentiated, Th17 cells produce cytokines IL-17A, IL-
17F, IL-21 and IL-22. We investigated how immunostimulatory molecules such as 
poly[di(sodium carboxylatoethylphenoxy)-phosphazene (PCEP), Alum, CpG 
oligodeoxynucleotide (CpG ODN), Curdlan, Leptin and Lipopolysaccharide (LPS), alone 
or in combination influenced differentiation and/or activation of Th17 type immune cells 
in mice. In vitro studies showed that murine splenocytes stimulated with CpG showed 
significantly induced production of IL-12, a cytokine important for induction of Th1 type 
immune cells and IL-12 is known to be inhibitory for differentiation of Th17-type 
immune cells. Curdlan + Leptin +/- PCEP and PCEP + Curdlan induced significant 
expression of TGF-β. No immunostimulant combination induced both IL-6 and TGF-β, 
which we anticipated would be required for Th17 cell differentiation. When we 
investigated the cytokines induced by the immunostimulants 48 hours after injection in 
muscle tissue, we determined that Curdlan + Leptin significantly induced production of 
IL-17, likely from activation of already differentiated T cells. TGF-β was significantly 
induced in response to Curdlan and Leptin, alone and in combination but they were poor 
inducers of IL-6. PCEP+/- CpG or LPS significantly induced expression of IL-6 but not 
TGF-β. Finally, we immunized mice via intramuscular (i.m.) route with OVA in the 
presence of the immunostimulatory adjuvants and assessed cytokine production from 
OVA-restimulated splenocytes 5 weeks later. ELISA results indicated that OVA-specific 
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IL-17 production was significantly induced in splenocytes from mice immunized with 
PCEP + OVA relative to the mice immunized with Curdlan + OVA, although it was 
insignificant with respect to the OVA immunization group presumably due to the highly 
variable responses. Using flow cytometric analysis, we observed that vaccination with 
PCEP + OVA and Curdlan + Leptin + OVA significantly induced the frequency of OVA-
specific splenic CD4+IL-17+ cells. Curdlan + Leptin also significantly induced the 
frequency of OVA-specific CD4+Foxp3+ cells and CD4+IL-17+Foxp3+ double positive 
cells. Thus, we conclude that in vitro studies are poorly predictive of the type of adaptive 
response that may be induced when immunostimulatory adjuvants were used in a 
vaccine. Furthermore, vaccines formulated with PCEP and Curdlan + Leptin adjuvants 
promote Th17 cell differentiation and should be investigated as a combinational adjuvant 
for bacteria or fungal based immunizations.  
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CHAPTER 1  Introduction 
 Vaccines are highly important tools in public health that can protect against 
infectious diseases and even types of cancer [1-3]. Subunit vaccines are safe because they 
cannot revert to virulence but they often fail to promote a robust immune response. For 
more than 80 years, adjuvants have been included in vaccines to promote a more robust 
immune response to subunit vaccine antigens [4-6].  Different adjuvants mount different 
immune responses and therefore it is important to identify the mechanisms behind how 
each adjuvant works to select the adjuvant(s), which promotes the most appropriate 
immune response to combat each particular infection. 
Although excessive activation may lead to induction of autoimmune diseases, 
Th17 type immune cells are effective in combating bacterial and fungal infections, 
especially at mucosal surfaces [7]. It is important to identify adjuvants that promote 
Th17-type immunity for use in future vaccines and immunotherapies against these 
pathogens.  
I hypothesized that PCEP alone or in combination with other adjuvants, will 
promote an antigen-specific Th17-type of immune response when formulated as part of a 
vaccine. We were also interested to see whether in vitro assays may garner critical clues 
as to the type of adaptive immune response generated with adjuvants when formulated as 
part of a vaccine.  
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CHAPTER 2  Literature Review  
2.1 Adjuvants 
For more than 80 years, adjuvants have been included in vaccines to promote a 
more robust immune response to subunit vaccine antigens [4-6]. Adjuvants stimulate the 
innate immune response which educates and directs the adaptive immune responses so 
that it is more effective against individual pathogens. There is no universal mechanism of 
action by which adjuvants mediate their effects; some immunostimulatory adjuvants 
promote innate immune cells to secrete select cytokines which promotes T cell 
differentiation [8]. Other adjuvants promote antigen presentation and activation of 
antigen presenting cells (APCs), which are important to initiate the adaptive immune 
response [9]. Inclusion of adjuvants can reduce the dose of antigen required for an 
effective vaccine; a process known as dose-sparing which is an important economic 
factor in vaccine production [10]. Even with all of the current research and knowledge on 
the benefits of adjuvants in vaccines, there are still few adjuvants approved for use in 
human vaccines.  
 
2.1.1 Adjuvant History 
The word “adjuvant” was derived from a Latin word, “adjuvare” meaning “to 
aid” [11]. Adjuvants have been known as an immunologist’s “dirty little secret” because 
although they have been used in vaccines for almost a century to trigger induction of 
robust immune responses, their mechanism of action remain poorly understood [12].  
Vaccine development evolved from ingenious but risky experimental trials. In 
England, dairymaids were routinely exposed to cowpox during daily milking and they 
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experienced a mild immune response to cowpox, but they tended not to suffer from 
smallpox infection. To test whether cowpox infection could protect against small pox 
infection, country physician Edward Jenner in 1776 took fluid from a cowpox pustule 
from a dairymaid and vaccinated 8-year-old James Phipps [13, 14]. Later, he repeatedly 
attempted to infect Phipps with smallpox but the boy never developed the disease [13, 
14]. Although it took many years, vaccination was eventually accepted by the medical 
establishment as an important means to prevent disease. From there, vaccines were 
created for different diseases such as polio (Jonas Salk, 1955; commercialized by Albert 
Sabin in 1961), measles (Dr. Peebles and Dr. Enders, 1963), diphtheria (Franklin Royer 
developed adequate doses of antitoxin, 1905; commercialized by Mulford Company of 
Philadelphia, 1920’s), influenza (Ernest Goodpasture, Thomas Francis, Jonas Salk, 
Wilson Smith & Macfarlane Burnet, 1930s; US Military, 1940s) and many more [15].  
Vaccines are important tools to protect domestic and livestock animals against 
infections. The first known use of an adjuvant in veterinary studies was by veterinarian 
Dr. Gaston Ramon who determined that substances added to a vaccine to produce an 
inflammatory response at the site of injection resulted in increased antibodies in sera [15]. 
In the 1930’s, Alexander Glenny commercialized the use of aluminium salts (or alum) as 
an adjuvant in a human vaccine for pertussis and alum has since been commercialized in 
many human and animal vaccines [15]. Other early vaccine adjuvants include mineral 
oil-in-water emulsion known as Complete and Incomplete Fruend’s Adjuvant (CFA and 
IFA) and Emulsigen, which promote strong antigen-specific humoral and cellular 
immune responses to vaccine antigens [15, 16]. However, CFA, IFA and Emulsigen have 
not been approved for commercial use in human vaccines in the United States of America 
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(USA) and Canada due to excessive reactogenicity. Recently, AS04 [a combinational 
adjuvant consisting of monophosphoryl lipid A (MPL) and alum] and MF59 [a squalene 
(a natural and easily metabolized oil), oil-in-water emulsion] adjuvants were approved for 
use in vaccines for the human papilloma virus and influenza, respectively [17, 18]. AS04 
is not immunostimulatory as it is able to induce an immune response only when 
administered in combination with an antigen [9, 18]. MF59 has both high 
immunogenicity and low reactogenicity [9, 19]. Overall, there are fewer adjuvants 
licensed for use in human vaccines than veterinary vaccines as safety regulations are 
much more stringent for human administration. Licensed adjuvants approved for use in 
veterinary to human vaccines vary in different countries as not all nations have the same 
safety standards. For example, a liposomal adjuvant, which consists of lipid layers and 
encapsulate antigens, has been approved for use in a Hepatitis A vaccine in Europe but it 
has not yet been approved for commercial use in North America [20].   
Research on adjuvants has evolved from using one adjuvant to promote an 
immune response to coadministering adjuvants in an attempt to mount coordinated or 
fine-tuned responses to pathogens [21, 22]. In 2011, an intradermal (i.d.) influenza 
vaccine containing adjuvant JVRS-100 was approved by the FDA [23-26]. JVRS-100 is a 
cationic liposome-DNA complex (CLDC) made up of cationic DOTIM/cholesterol 
liposomes and plasmid DNA, which has been shown to increase CD4+ and CD8+ T cell 
and antibody responses [27, 28]. Although select adjuvants are becoming commercialized 
and being used in vaccines today, there is still much research needed to be carried out to 
determine safety, efficacy and mechanisms of action.  
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2.1.2 Mechanisms of Action 
Adjuvants have been classified by parameters such as their mechanisms of action, 
their source, or their physiochemical properties [29]. Edelman further refined the 
classification to these 3 categories: 1) immunostimulants which increased cytokine 
production and in turn leads to immune cell recruitment their immunomodulation, 2) 
carriers (immunogenic protein, virus vectors, outer membrane proteins, fatty acids, etc.) 
which provide T cell help through immunogenic proteins to increase antigen recognition 
and 3) vehicle adjuvants which create matrices for antigens to induce immune responses 
[30].  For example, water-in-oil emulsion adjuvants such as CFA (Complete Freund’s 
Adjuvant) create a depot, which allows for the slow release of the antigen from the 
injection site [31]. This slow release ensures that there will be antigen present in the 
system for an extended period of time, creating more exposure, which can also lead to 
increased antibody titres [32]. Cytokines and chemokines are important components of 
any immune response that promote the recruitment of local immune cells. Alum, CpG 
and MF59 have been shown to activate “adjuvant core response genes”, which in turn 
code for proteins that are known to increase cytokine-cytokine receptor interaction, host-
pathogen interaction and can be characterized through the up-regulation of cytokines, 
chemokines and adhesion molecules, which all are associated to a healthy inflammatory 
response linked to vaccine adjuvanticity [33].  
MF59 promotes recruitment of neutrophils, monocytes, macrophages and DCs at 
the site of injection in mice as well as increased antigen presentation on APCs [17]. 
Although it is not fully understood, antigen adsorbs onto Alum and interacts with lipids 
on the surface of the DCs through an abortive phagocytosis then the DCs internalize the 
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antigen leading them to initiate antigen presentation[17]. Alum does not directly affect 
APC maturation, it promotes APC activation by enhancing the surface expression of 
MHC class II and costimulatory molecules on the surfaces of APCs which is a 
requirement for T cell activation in immune responses [34, 35]. CpG and LPS induce 
maturation and activation of DCs through Toll-like receptors (TLRs), costimulatory 
molecules and a cluster of differentiation molecules [18, 36, 37]. CpG binds to TLR9 
whereas LPS and AS04, which includes MPL (Monophosphoryl lipid A), bind TLR4; all 
of which activate signalling cascades [18, 38-40]. Adjuvant AS04 stimulates DC 
activation through TLR4 pathway signalling [18].  
The inflammasome is an important complex for the innate immune response in 
myeloid cells [9, 41]. The inflammasome is a complex assembly of proteins that are 
activated by NOD-like receptor (NLRs) binding [9] or damage-associated molecular 
patterns (DAMPS) [42, 43]. Upon activation, the inflammasome activates caspase-1, 
which cleaves pro-forms of IL-1β, IL-18 and IL-33, which then activates the release of 
active forms of these cytokines. It is reasoned that adjuvants that activate the 
inflammasome will promote a more effective vaccine response [9].  
 
2.1.3 Alum 
Alum is the generic name for an adjuvant based on aluminum salts (aluminum 
hydroxide and magnesium hydroxide) and is the most common commercial adjuvant. . 
Alum promotes an increase in the recruitment of antigen presenting cells, including 
monocytes and macrophages to the site of injection as well as increased expression of 
cytokines and chemokines by these recruited cells [44-46]. When included in a vaccine, 
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alum has been shown to promote increased antigen-specific antibody production and 
Th2-type immune responses [15, 47, 48] as well as facilitation of antigen uptake into DCs 
through promoting antigen adsorption onto DC membrane lipids [49]. The DC then 
phagocytizes the antigen and antigen presentation is initiated [50]. In vitro experiments 
with murine and human DCs and macrophages suggest that Alum signals through NLRP3 
to promotes activation of the of inflammasomes [51]. However, it is not definitively 
whether alum-induced inflammasome activation is a necessary for its adjuvant activity 
[44, 46, 51, 52]. 
 
2.1.4 LPS 
Lipopolysaccharides (LPS) are one of the largest components of the Gram-
negative bacterial cell wall and it is comprised of 3 major components: lipid A 
(endotoxin), core-oligosaccharide and O-antigen [53].  Endotoxin is crucial in 
maintaining bacterial outer membrane integrity, while the core-oligosaccharide is 
structural and the O antigens are variable, made up of repeating units of 3-5 highly 
versatile monosaccharides [53-55]. LPS induces a Th1 response through TLR4 signalling 
pathway and activates MyD88 to promote expression of IL-1β, IL-12, IL-18 and IFN-β as 
well as IFN-γ, through activation of transcription factor NF-κB [56-60]. LPS promotes 
DC maturation [61-63]. Because it is such as robust inducer of inflammation and fever, 
LPS can lead to deaths and has been deemed unsafe to use in a vaccine but it is still 
widely used for in vitro experimentation [64]. AS04, a combination of derivative of LPS 
known as Monophosphoryl lipid A (MPL, previously stated) and an aluminum salt, 
promotes equivalent immunomodulatory actions while being much less toxic than LPS 
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[65]. MPL is used in HPV vaccines and is also being investigated as a veterinary vaccine 
adjuvant [18, 66]. 
 
2.1.5 PCEP: Polyphosphazene 
Polyphosphazenes have only been used as experimental vaccine adjuvants in the 
last 2 decades. They are water soluble polymers comprised of a phosphorous-nitrogen 
backbone with organic side-chains attached to the phosphorous molecules [67]. They 
induce expression of “adjuvant core response genes”, which includes increased 
expression of chemokines, cytokines, innate receptors, interferon-induced genes and 
adhesion molecules [68]. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) was one of 
the first polyphosphazenes to be studied as a vaccine adjuvant [21, 69]. It proved to have 
low reactivity at the site of injection and when administered intranasally to mice with 
influenza antigen, it induced a balanced Th1/Th2 response [70] as well as long-term 
memory B cells that produce antigen-specific IgG and SIgA antibodies in mucosal and 
systemic sites [70]. Another polyphosphazene, poly[di(sodiumcarboxyl-
atoethylphenoxy)phosphazene (PCEP) was shown to induce a superior and 
predominantly Th1 type immune response relative to PCPP adjuvant and alum when 
formulated with bacterial and viral antigens in pigs and mice [71, 72]. PCEP is able to 
induce cytokines and chemokines secretion at the site of injections, to recruit T and B 
cells as well as induce expression of adjuvant core response genes IL-1β, IL-6, IL-18, 
IFNγ, TLR4, TLR9, CCL-2, CCL-12, Ltbr4 and NLRP3 genes [68, 73]. Andrianov et. al 
suggested that polyphosphazenes activate select TLRs but there is no evidence to support 
this theory [74]. Intramuscular injection of PCEP into mice led to increased recruitment 
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of neutrophils, macrophages and lymphocytes with more modest recruitment of 
monocytes and DCs. Flow cytometric analysis showed that the recruited myeloid cells 
may internalize PCEP, although how recruitment of distinct immune cells to the site of 
injection potentiates immune responses to antigens is not yet understood [73]. Research 
in the Mutwiri laboratory is being performed to refine our understanding of how PCEP 
mediates its mechanisms of action and how it can be used to promote effective vaccines.  
 
2.1.6 CpG Oligodeoxynucleotide 
CpG oligodeoxynucleotide (ODN) is a synthetic oligodeoxynucleotide which 
contains one or more unmethylated CpG dinucleotides of CpG motifs [75]. Bacterial 
DNA is unmethylated and activates immune cells [76, 77] whereas methylated vertebrate 
DNA does not [78]. Unmethylated CpG dinucleotides act as bacterial DNA mimetic and 
TLR9 agonists that mediate B-cell survival, activation and differentiation [39, 75, 79]. 
Further, upon recognition of the CpG molecule to TLR9 in the endosome, CpG induces 
signalling of TRAF6 and IRAK through a MyD88 signalling pathway, which induces 
production and nuclear translocation of transcription factor NF-κB and induced 
expression of IL-1, IL-6, IL-12, IL-18, IFNγ and TNF-α [9, 39, 40, 80-82]. Through this 
cascade of events, CpG induces a Th1-type of immune response. When CpG is co-
administered with other adjuvants, such as a polyphosphazene, it promotes a more 
balanced Th1/Th2 response [21, 22, 79]. 
 
2.1.7 Curdlan 
Curdlan is a water-insoluble β-glucan polysaccharide from the cell wall of soil 
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bacterium Alcaligenes faecalis [83-85]. It’s a high molecular weight linear polymer 
consisting of β (1-3) linked glucose residues and has immunostimulatory qualities and is 
a Dectin-1 agonist [83-85]. Curdlan binds to Dectin-1, a C-type lectin receptor on DCs, 
that binds to pathogen-specific carbohydrate residues on select pathogens or yeast [86, 
87], which in turn recruits Syk, a tyrosine kinase critical for cytokine production from 
cells [88]. Through this signaling cascade, Dectin-1 recognition of Curdlan on a DC, 
promotes secretion of proinflammatory cytokines from the DC: IL-6, TNFα and IL-23 
which in turn instruct the differentiation of CD4+ Th17-type cells in mice [83, 85, 86]. β 
– glucans like Curdlan can also NLRP3 inflammasome activation dependent on the 
Dectin-1-syk pathway, which is linked to the activation and secretion of IL-1β [84]. Lack 
of Dectin-1 or its loss of function can lead to an increased chance of pathogenic fungal 
infections in both humans and mice [83, 89, 90]. When T regulatory cells (Tregs) are 
present and secreting TGF-β and IL-6, signaling through Dectin-1-Syk can induce Th17 
differentiation and therefore induction of a Th17-type immune response. In response to 
Curdlan, DCs produce IL-23 instead of IL-12 and IL-23 acts on differentiated Th17 cells 
to further support Th17 proliferation [86, 91]. In contrast, CpG triggers induction of IL-
12 from DCs, which would trigger a shift from Th17 to Th1 type CD4+ T cells. 	
2.1.8 Leptin 
The protein Leptin is a member of the long-chain helical cytokine family (which 
includes IL-6 and IL-12) produced by adipose tissue (an adipokine) and circulates in 
plasma [92, 93]. Leptin serves to aid in sustaining energy in times of starvation by 
slowing down metabolism [94]. Injection of Leptin into an obese mouse can produce up 
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to 30 % weight loss which suggests that it plays a significant role in weight regulation 
[92]. The Leptin receptor is expressed on the surface of peripheral and bone marrow 
derived immune cells as well as in cells in major organs and muscle [95-98]. Leptin 
promotes the activation of natural killer cells (NK), neutrophils and the secretion of TNF-
α, IL-6 and IL-12 from macrophages and granulocyte chemotaxis during an innate 
immune response [93, 99]. In the adaptive arm of the immune system, leptin inhibits Treg 
production and stimulates proliferation of naïve T cells into Th1 or Th17 cells [100, 101] 
through expression of transcription factor RORγt (ROR nuclear hormone receptor family) 
and STAT3, both regulators of Th17 differentiation [93]. Unfortunately, high serum 
leptin concentrations in mice has been associated with development of autoimmune 
diseases such as experimental autoimmune encephalomyelitis (EAE; similar to multiple 
sclerosis) so it may not be safe to use excessive quantities of leptin as a vaccine adjuvant 
to promote a Th17 type immune response [102].  
 
2.2 Innate Immune Response 
The immune system can be categorized into two groups: the innate immune 
system and the adaptive immune system. NK cells, mast cells, basophils, DCs, 
neutrophils and macrophages contribute to the innate response which is a non-specific 
first line of defence against pathogens [8]. Proteins in the blood, which include the 
complement system proteins among others, aid in initiating an inflammatory response, 
characterized by redness, heat, swelling and pain [8]. Activated mast cells release 
histamines which causes vasodilation of the nearby vessels while DCs (Langerhan’s 
cells) and dermal macrophages release cytokines to induce high endothelial venules to 
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present adhesion molecule, cytokines or receptors in order to aid in diapedesis [8]. 
Leukocytes can also act as primary response cells that can kill the pathogens foreign cells 
[8]. Neutrophils are recruited through the blood vessel walls during inflammation via 
diapedesis or extravasation by chemoattractants and chemokines and they phagocytize 
the pathogen or antigen [8]. Once monocytes migrate out of the blood, they undergo 
maturation and differentiate into macrophages that process antigen and express cytokines 
to further augment inflammation in the local environment [103]. Neutrophils and then 
macrophages phagocytose the pathogen and release cytokines and chemokines to signal 
other innate immune cells and activate inflammation [8]. DCs are the major APC for T 
cell activation, aiding in the activation of adaptive immunity and upon antigen uptake, 
DCs undergo a maturation process, including the presentation of receptor CCR7 on their 
surface, which recognises chemokines CCL19 and CCL21 and causes them to migrate 
towards the lymph nodes (LN). 
 
2.3 Adaptive Immune Response 
Together the innate and adaptive arms of the immune system provide host 
defence. The adaptive immune response is activated by the innate immune response and 
it is much more specific toward select antigens rather than molecular patterns. Humoral 
or antibody-mediated immunity acts using antigen-specific antibodies from activated B 
cells and plasma cells that bind to the antigen/pathogen, attempt to neutralize the 
infection and/or eliminate the antibody-bound pathogen through effector mechanisms 
such as phagocytosis or cell lysis [8]. The cell-mediated immune response is mediated by 
CD4+ and CD8+ T cells, like Th1 and CTLs, respectively [104]. CTLs recognize antigens 
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through MHC class I on other infected cells and this recognition activates CTLs to kill 
infected cells matching the antigen at the site of infection through apoptosis by the 
secretion of perforin and granzymes or through Fas ligand attaching to Fas on the 
infected cells [8, 104]. CTLs, similar to Th1 cells, also secrete the cytokine IFNγ, which 
activates macrophages at the site of infection [8]. T helper cells are activated by APCs, 
mainly DCs, in the paracortex of the draining LN [8]. We will later discuss T helper cell 
differentiation of the cell-mediated immune response in more detail.  
 
2.3.1 B cell activation 
For a B lymphocyte to become activated, the surface immunoglobulin (antibody) 
known as the B cell receptor (BCR) must bind antigen that is most likely loose from 
infection in the lymph, migrating to the LN or is passed to it from follicular DCs in the 
draining LN [8, 105, 106]. Once a BCR binds its specific antigen, the antigen gets 
internalized then presented onto its MHCII on the cell surface. The B cell presents 
antigen on MHCII to an activated follicular T helper cell in the germinal centre of the LN 
(The immunological synapse between the B and T cells is explained below). Only the 
cognate activated follicular T helper cell can bind to the presented antigen but then it 
secretes cytokines to activate the B cell, which can then lead to class switching [8]. This 
class switching is dependent on the cytokines produced by the follicular T helper cell, 
and will cause the B cell to become either effector B cells (plasma cells) or memory B 
cells [8]. Plasma cells migrate to the bone marrow where they secrete antibodies that 
migrate through the blood vessels, the lymphatic system or to the site of infection for 
protection against the pathogen.  
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2.4 Naïve T Cells 
Naïve T cells originate in the bone marrow and migrate to the thymus where they 
develop from lymphoid precursor cells with the help of thymic epithelial cells [107]. 
Thymic epithelial cells express both MHC molecules and the lymphocyte will become 
either a CD4+ naïve T cell (MHC class II) or a CD8+ naïve T cell (MHC class I), based 
on which receptor binds to the thymic epithelial cell [8]. Cells just arriving to the thymus 
are called double negative thymocytes as they currently do not express a TCR, CD4 or 
CD8 molecule [8]. However, express a precursor receptor called TCR-β, which allows 
the cell to continue to proliferation and avoid early apoptosis [8]. Once in the thymus, 
Rag-1 and Rag-2 protein expression on the thymocytes will cause rearrangement of TCR 
genes in these cells, later allowing for the thymocytes to present both CD4 and CD8 
TCRs on its surface [8]. Until a naïve thymocyte’s interaction with the thymic epithelial 
cells, they are double positive for both CD4 and CD8 molecules [8]. Epithelial cells 
expressing self peptides on both MHC class I and class II loosely bind to the double 
positive TCR of thymocytes causing them to become either CD4 or CD8 linage [8]. It is 
currently unknown if this is due to random processes or through specific unknown signals 
in the thymus [8]. The process of positive selection allows healthy T cells that recognize 
self- antigen or MHC molecules to survive and again avoid apoptosis, while another 
process known as negative selection aids in the destruction and apoptosis of those cells 
binding strongly and reacting to self-antigen [8]. These mechanisms are important for 
proper T cell development and immunity, avoiding pathogenesis. Mature but naive CD4+ 
and CD8+ T cells migrate from the thymus and circulate in the blood stream and 
lymphatics. 
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Naive T cells interact with DCs in the paracortex of the LN [8]. Extensive 
experimentation has revealed that there is a high degree of diversity in T-cell–DC contact 
dynamics which may be responsible for fine-tuning the T-cell activation process [108, 
109]. At first, a CD4 molecule on the T cell binds to the MHC class II complex on the 
DC (or alternatively CD8 molecules of CD8+ cells bind to MHCI on the DC). The T cell 
receptor (TCR) recognizes antigen being presented on the MHCII complex and then 
binds to the complex [8]. Next, the CD40 ligand on the T cell binds with CD40 on the 
DC causing B7 molecules to be expressed on the DC cell surface, which in turn bind 
CD28 on the T cell and ICAM-1 on the DC, respectively which promotes stability during 
activation [8]. After binding with the naïve T cell, the DC expresses cytokines to aid in 
the differentiation of the naïve T cell into a CTL (in the case of CD8 T cells or T helper 
cell or T regulatory cell in the case of CD4+ T cells. The type of cytokines produced by 
the DCs influence into which specific T cell subset the naïve CD4+ T cell will 
differentiate [8]. Following these steps, the DC begins to secrete IL-2 which prevents T 
cell apoptosis and the T cell begins to undergo activation of the T helper lineage [8]. 
Multiple signals from the DC, many of which are not yet fully understood, educate the T 
cell about where they need to migrate in the body to combat the pathogen and what type 
of T cell response would be most appropriate to combat the infection [110-112]. Each T 
helper subtype and regulatory T cells have transcription factors that act as master 
regulators to promote their differentiation. Over time, cytotoxic T-lymphocyte antigen 4 
(CTLA4) surface expression is increased which down-modulates T-cell activation 
following antigen recognition [111]. 
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It wasn’t until the 1980’s that different subsets of CD4+ T cells were characterized 
[113]. CD4+ naïve T cells can differentiate into Th1, Th2 and Th17 helper cells as well as 
Tregs. Upon activation, effector and memory lymphocytes combat pathogens and reduce 
the response time upon reinfection, respectively [8]. Memory lymphocytes have a much 
longer life and migrate through the body until they recognize their cognate antigen and 
mount a much quicker response than do naïve T cells [8]. T regulatory cells contribute by 
maintaining homeostasis through self-tolerance as well as oral tolerance, maternal 
tolerance to fetus and feedback control of responses produced by the T helper cells [114-
117]. Figure 1-1 portrays the cytokine and transcription factors required for naïve T cells 
to differentiate into T helper (Th) or T regulatory cells (see blue arrows). The two key 
factors contributing to the differentiation of Th cells from naïve T cells are the cytokine 
environment and the activation of Th cell specific transcription factors [113].  
 
2.4.1 Th1 cells 
Th1 and Th2 cells were characterized in 1986 by scientists Coffman and 
Mosmann as each subset produced different cytokines upon activation [118]. Th1-type 
cells are CD4+ effector T lymphocytes characterized by the expression of IFNγ, IL-2 and 
TNFα, while Th1’s transcription factors (master regulators) are T-bet and STAT4 [113]. 
STAT4 as well as STAT1 are induced by the production of IL-12 and IFNγ, respectively 
and aid in the binding of T-bet to the T cell [119, 120]. Th1-type cells are associated with 
a cell-mediated type of response as they activate macrophages through increased IFNγ 
production [113, 121]. Th1 cells recognize antigens through MHC class II on infected 
macrophages and further activate macrophages to destroy the antigen, while, upon 
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activation, these T cells produce cytokines which induce antigen-specific production of 
cytokines by effector and memory T cells [8]. Th1 contributes to the development and 
maintenance of memory CD8+ T cells but are not required for CD8+ T cell activation 
[122]. Pathogenesis due to excessive Th1 production can lead to organ-specific 
autoimmune diseases [113].  
 
2.4.2 Th2 cells 
Th2 cells differentiation requires the APC to express IL-4 while Th2 cells 
themselves produce a combination of IL-4, IL-5, IL-13 and IL-25 with IL-2, IL-7 (Figure 
1-1) as well as TSLP and the master regulator GATA3 and STAT5. STAT5 is induced by 
the production of IL-4 and aids in the binding of GATA3 to the T cell [123]. Th2-type 
cells are associated with the humoral immune response as they promote antibody 
production of IgE, eosinophil and mast cell recruitment and activation and extracellular 
parasite clearance through the production of cytokines and neutralizing antibodies IgG  
[8, 113, 124]. Pathogenesis can occur due to excessive Th2 production, which can cause 
diseases such as asthma and other allergic reactions [113]. 
 
2.4.3 T regulatory cells 
Tregs, also known as suppressor T cells, attempt to restore homeostasis to a 
system by suppressing an activated immune response, which is critical to minimize 
potential pathogenesis [8, 125]. Differentiation of Tregs from naïve T cells occurs in 
response to transformation growth factor-β (TGF-β) or IL-2 exposure (Figure 1-1), which 
leads to activation of the Treg’s master regulator Foxp3 alongside STAT5 [126]. STAT5 
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is induced by the production of IL-2 and aids in the expression of Foxp3 in the Treg cell 
[127]. Tregs produce cytokines IL-10, IL-35 and TGF-β and can be identified by 
measuring IL-10 or Foxp3 in a CD4+ T cell, for Treg development and proliferation [125, 
126].	
 
 
2.4.4 Th17 cells 
In 2005, scientists were exploring a homolog of the IL-12 family, p19 (now 
referred to as IL-23) as it formed a heterodimer with the p40 chain of IL-12. They 
conducted an experiment with IL-12 and IL-23 knockout mice, which determined that 
there was indeed another subset of T helper cell induced by IL-23 and that this CD4+ 
effector T lymphocytes was characterized by the expression of IL-17A, IL-17F, IL-21 
and IL-22 (Figure 1-1) [128-130]. Th17 cells are differentiated from naïve T cells in the 
presence of both TGF-β and IL-6, produced by stromal cells and DCs, respectively, and 
are further upregulated in the presence of IL-1β and IL-23, produced by DCs and 
macrophages at the site of infection [131-133]. DC will produce IL-6 and IL-1, while 
many other stromal cells will produce the TGF-β needed for Th17 cell differentiation [8, 
132]. Under circumstances where there is TGF-β but limited IL-6, IL-21 will also 
promote Th17 differentiation [7, 132]. The IL-6 from the DC and TGF-β from other cells 
allow for ideal Th17 cell differentiation conditions [8, 132]. IL-6 and IL-1 promote 
transcription factor RORγt expression in the Th17 cell and IL-6 from the DC also 
promotes STAT3, the master regulators activated to aid in development and proliferation 
of Th17 cells and expression of its cytokines [8, 113, 132]. STAT3 is induced by the 
production of IL-6, IL-21 and IL-23 and aids in the expression of RORγt in the T cell 
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[134]. STAT 3 is also able to down-regulate T-bet, GATA3 and Foxp3 expression, 
alluding that STAT3 is able to supress a Th1, Th2 or Treg-type of immune response, 
allowing a Th17-type of immune response to be produced [134]. Th17 cells present 
CCR6 on its surface, which recognizes and binds to chemokine CCL20, produced by 
tissue cells and macrophages at the site of some bacterial and fungal infections [8, 132].  
Th17 cells are most commonly found in the mucosa and secretion of IL-17 
activates epithelial cells to recruit leukocytes to fight bacterial and fungal infections. 
Through cytokine expression, Th17 cells are able to induce inflammation and recruit 
leukocytes, mainly neutrophils as well as some monocytes to the site of infection [8, 
132]. Some research has shown that an imbalance of Treg to Th17 cells increases the 
chance of disease inflammatory and autoimmune diseases onset [135-137].  However, 
Th17 cells have a high plasticity and are unstable effector cells, meaning they may 
convert into another T helper cell or even a T regulatory cell under certain conditions. 
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Figure 1-1. Differentiation of naïve T cells. Naïve T cells differentiate into T helper and 
T regulatory cells after binding with APCs carrying antigen. The APC in turn expresses 
cytokines that bind with the naïve T cells inducing expression of transcription factors 
inside the cells causing production of cytokines associated with the T helper and 
regulatory cells [113, 132].  
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2.4.4.1 Differentiation Characteristics and Plasticity 
Even under the optimal conditions for Th17 cell development, Th17 cells can be 
induced to differentiate into another T helper cell subset, as T helper cells are highly 
plastic. Th1 and Th2 are able to convert into the other classes of cells at an early stage of 
differentiation, most often seen as a switch from Th1 to Th2 or visa versa [113]. Treg and 
Th17 cells can be influenced to convert into other T cells at both early and late stages of 
differentiation [113]. For example, Curdlan, one of the adjuvants in this study has been 
observed to cause a switch from CD4+Foxp3+ Tregs to CD4+IL-17+ Th17 cells [85]. 
Research has shown that Th17 cells when exposed to IL-12 can produce IL-4 or IFNγ, 
often while also producing IL-17, which shows us there is a conversion or even a mixed 
cell response [113]. This plasticity makes it difficult to pinpoint conditions for induction 
of a Th17-type of response. 
 
2.4.4.2 Protection 
Th17 are large contributors to protection against bacterial and fungal infections 
due to their presence in the mucosa, production of antimicrobial peptides like human β-
defensins, mediated by the production of IL-17 and IL-22 and recruitment of neutrophils 
[7, 138-140]. Th17 cells express chemokine receptor CCR6 and cytokines GM-CSF 
(granulocyte macrophage colony stimulating factor), which aid in the recruitment of 
neutrophils at the infection site [7, 138]. Another study showed that Th17 cells can 
activate CTLs [141, 142]. 
There is evidence for a protective role against tumors [141]. Th17’s role in 
protection against tumors comes from the production of CD8+ CTLs and chemokines like 
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CXCL-8 and CXCL-2 as well as CCL20, which promotes DC recruitment within a tumor 
leading to activation of CD8+ T cells [142, 143]. Th17 cells within the tumor also 
stimulate the tumor to express CCL20, recruiting the CD8+ T cells to their location, 
expressing perforin/granzyme B to kill the tumor cells [141-145].  
 
2.4.4.3 Side-effects and implications of Th17-type cell activation 
Th17 cells are a recent discovery with respect to T helper cell immunity. Research 
for immunotherapies has been limited, as it was believed that Th17 cells and the Th17-
type of immune response mostly aided in pathogenesis and autoimmune diseases. When 
Th17 cells are increased and there is an imbalance with Treg cells, the result can be 
chronic and severe inflammation, which may lead to diseases such as cystic fibrosis and 
multiple sclerosis [138, 146]. These negative Th17-type observations have impeded 
beneficial research for vaccines and immunotherapies linked to a positive and balanced 
Th17-type of immune response.  
 
In summary, Th17 cell’s high degree of plasticity and low stability may make it 
difficult to identify adjuvants that can lead to the establishment of a safe, protective and 
effective Th17-type immune response. Thus, research towards identifying adjuvants that 
can promote a balanced Th17-type response may prove to be challenging but rewarding 
for future vaccine candidates against bacteria and fungi. 
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CHAPTER 3  HYPOTHESIS AND OBJECTIVES 
3.1 HYPOTHESIS 
PCEP, or another adjuvant, alone or in combination with other adjuvants, will 
promote a Th17-type of immune response.  
There were 3 main objectives to validate this hypothesis. 
 
3.2 OBJECTIVES 
Objective 1 
Perform murine in vitro studies to identify immunostimulatory adjuvants that 
induce production of cytokines IL-1β, IL-6, IL-12, IL-17, IL-23 and TGF-β that directly 
or indirectly influence Th17 cell differentiation. 
 
Objective 2 
Perform murine in vivo studies with adjuvants from Objective 1 wherein 
adjuvants are injected into muscle and then quantify local production of IL-6, IL-12, IL-
17 and TGF-β, which contribute to Th17 cell differentiation. 
 
Objective 3 
Immunize mice with Th17-inducing adjuvants, selected from Objectives 1 and 2, 
with an antigen to determine whether the adjuvant combination promotes an antigen-
specific Th17-type of immune response. 
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CHAPTER 4  MATERIALS AND METHODS 
4.1 Animal Experiments 
All animal experiments were conducted according to the Guidelines for the Care 
and Use of Laboratory Animals as indicated by the Canadian Council on Animal Care 
and was approved by the Animal Care Committee of the University of Saskatchewan. In 
objective 1, fifteen BALB/c mice (Charles River) were acclimatized for one week, mice 
were euthanized and then spleens from all fifteen mice were excised. The spleens were 
pooled in sets of three to make a sample size of five (n = 5) and splenocytes were isolated 
(see below).  
In objective 2, eighty-four BALB/c mice (n = 6 per group) were injected 
intramuscularly with 25 µL into both semi-membranous muscles with an 
immunostimulatory adjuvant or a combination of adjuvants. Blood and muscle tissue 
from the site of injection were harvested from all mice in every group at 48 hours post-
injection. 
In objective 3, one hundred and twenty BALB/c mice (n = 8 per group) were 
randomly allocated into eight groups with sixteen mice per group. On Day 0, eight naïve 
mice were euthanized and their spleens harvested. The remaining mice were immunized 
with OVA experimental antigen and the various immunostimulatory adjuvants. Mice 
were bled on day 0, 14, 21 and 35. On day 21, 8 mice from each group were euthanized, 
and had their spleen harvested. The 8 remaining mice from each group received a booster 
immunization on day 21 and were euthanized on day 35 and their spleens were collected.   
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4.2 Adjuvants 
The adjuvants used in this study were Alum, CpG ODN 1826, Curdlan, Leptin, 
Lipopolysacchride (LPS), PCEP (poly[di(sodiumcarboxylatoethyl-
phenoxy)phosphazene]). A list of adjuvants used and their sources are listed on Table 4-
1. PCEP was synthesized by Idaho National Laboratory (Idaho Falls, ID, USA) using 
methods described previously (Andrianov et al., 2004; Mutwiri et al., 2007a) and, prior to 
use, its endotoxin levels were determined to be less than 0.034 ng/ml as assessed by the 
Limulus Amebocyte Lysate assay (Biowhittaker, Walkersville, MD, USA). The adjuvant 
CpG ODN 1826 was class B, (5’-TCCATGACGTTCCTGACGTT-3’) and contains a full 
phosphorothioate backbone [Merial (Lyon, France)].  
 
4.3 Spleen Cell Isolation 
Spleens were placed into Minimal Essential Media (MEM) (Sigma Life Science) 
containing 10 mM HEPES (Lifetech, ThermoFisher Scientific, Waltham, Massachusetts, 
USA) and 50 U/mL Penicillin/Streptomycin (Gibco, ThermoFisher) and kept on ice, then 
minced and pushed through a 0.2 µm cell strainer using the end of a sterile glass syringe. 
Splenocytes were centrifuged at 350 x g for 10 minutes at 10 °C. Supernatant was 
discarded, pellet disrupted by knocking tubes together, 1 mL Gey’s solution (Red blood 
cell lysis buffer; (CaCl2 (0.220 g), KCl (0.370 g), KH2PO4 (0.03 g), MgCl2 (0.210 g, 
MgSO4 (0.070 g), NaCl (8.000 g), NaHCO3 (0.227 g), Na2HPO4 (0.120 g), D-glucose 
(1.000 g) in 1 L distilled water) (Sigma-Aldrich)) was added to the cells and incubated at 
room temperature (RT) for 10 minutes [147]. Cells were centrifuged at 350 x g for 10 
minutes at 10 °C after the volume was adjusted to 10 mL with PBS. Supernatant was 
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discarded and AIM V (Gibco) containing 10 % Fetal Bovine Serum (FBS) (Gibco), 50 
U/mL Penicillin/Streptomycin (Gibco) and 0.1 µM β-mercaptoethanol (Gibco) was added 
to the cells, centrifuged at 350 x g for 10 minutes at 10 °C and resuspended in AIM V 
10 % media again. Cells were counted using hemocytometer under standard protocol by 
diluting 1:4 in Trypan Blue (Gibco). 
 
4.4 Cell culture and stimulation 
 Splenocyte numbers were adjusted to a concentration of 1.0 x106 cells/well 
(1.0x107 cells/mL) and introduced into 96 well tissue culture plates (Thermofisher) at 100 
µL. They were incubated in a 37 °C, 5 % CO2 incubator for 1 hour to stabilize. 
Concentrations for immunostimulatory adjuvants for the in vitro and in vivo work are 
detailed in Table 4-1. Adjuvants in AIM V 10 % were added at 100 µL as a single, 
double or triple combination and incubated for 48 hours [68] before supernatants were 
collected and frozen at - 20 °C until used (Figures 5-1, -2 and -3 of the results section). 
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Table 4-1. Information for adjuvants, their manufacturer and the concentrations 
used of these adjuvants in the in vitro, injection and immunization studies. 
Adjuvant Manufacturer in vitro/ex vivo 
(µg/mL) 
Immunizations 
(µg/mL) 
Alum   Imject Alum, Thermo 
Scientific 
40 40 
CpG-ODN 1826  Coley Pharmaceuticals 
Group (MA, USA)  
1, 5 10 
Curdlan  Curdlan, Wako Pure 
Chemical Industry, Ltd. 
Japan 
1 10 
Leptin  Sigma Life Science 1 10 
LPS (E55:B5)  Sigma Life Science 1, 5 10 
PCEP  Idaho National 
Laboratories 
5, 25, 50, 125  50 
 
4.5 Adjuvant Injection Study 
Six to eight week old female BALB/c mice were ordered one week prior to 
injection study so that there were six mice per injection group. Mice were randomly 
placed into cages by Animal Care where they were allowed to acclimatize for a week 
prior to the study. No antigen was used in this study, only adjuvants diluted in PBS at pH 
7.4 (Gibco). Injections were administered to BALB/c mice per cocktail group at 25 µL 
per semi-membranosus muscle of each mouse for a total of 50 µL. Mice were euthanized 
48 hours after injections were administered (Figure 5-4 of the results section). 
 
4.6 Muscle Tissue Homogenization 
Forty-eight hours post-injection, the muscle tissue from the two sites of injection 
were excised from each mouse and placed into a 2 mL micro tube (VWR, North 
America) with 2.4 mm zirconia beads (Biospec Products, Inc.). The cells were 
homogenized in a MINI Bead Beater (Biospec Products, Inc.) at 48 (4800 osc/sec) for 10 
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seconds to disrupt the tissue and lyse cells. The 2 mL centrifuge tubes and all contents 
were frozen at - 20 °C such that when they are thawed in the future, we anticipate that the 
remaining intact cells may be lysed. At this time, the tubes were centrifuged (Sorvall 
Legent RT, Mandel) at 10, 000 x g for 5 minutes and the supernatant was removed and 
placed into PCR microplates on ice (Axygen Scientific) for ELISA analysis (Figure 5-4 
of the results section). 
 
4.7 Immunization Study 
Six to eight week old BALB/c mice were randomly assigned to an immunization 
group (n = 8 per group). The vaccines were comprised of 10 µg/mL Lyophilized 
Ovalbumin (Endograde, Hyglos), the antigen, with immunostimulatory adjuvants 
(concentrations are detailed in Table 4-2). Mice were vaccinated on Day 0 with 25 µL 
into both semi-membranosus muscles of each mouse for a total of 50 µL. An i.m. booster 
was administered into the semi-membranosus muscles with the same quantity as the 
primary immunization on Day 21 and mice were euthanized on Day 35 to harvest 
spleens. Blood sera were collected into SST tubes (BD Biosciences) from tail bleeds for 
further analysis on Day 0, 14, 21 and 35. SST tubes were centrifuged at 2000 x g for 20 
minutes then the supernatant was removed and placed into a 96 well PCR plates and 
frozen at -20 °C until needed (Figure 5-5, -6 and -7 of the results section). 
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Table 4-2. Immunization conditions for each treatment group. Antigen and adjuvant 
concentrations, which were diluted into 2 mL PBS (Gibco) and administered at 25 µL per 
semi-membranosus muscle for a total of 50 µL per mouse. 
Group Immunization Dose  
A Naïve 
B OVA 10 µg/mL 
C OVA 10 µg/mL + 50 µg/mL PCEP  
D OVA 10 µg/mL + 10 µg/mL Curdlan  
E OVA 10 µg/mL + 10 µg/mL Leptin  
F OVA 10 µg/mL + 50 µg/mL PCEP + 10 µg/mL Curdlan  
G OVA 10 µg/mL + 10 µg/mL Curdlan + 10 µg/mL Leptin  
 
 
4.8 Cytokine Detection in Mice (ELISA) 
 ELISA- R&D Systems Duoset kits (Fisher Scientific): IL-1β, IL-4, IL-6, IL-10, 
IL-17, IL-21 and IL-23, IFNγ and TGF-β were used throughout this study as per protocol 
provided by R&D Systems, Fisher Scientific. IL-12 was purchased from BD Biosciences 
and used exactly as protocol from the R&D Duoset kits. All assays were performed on 
Immulon II, 96 well microtiter plates (VWR), quantified with a Spectramax Plus384 
(Molecular Devices) and analyzed on Softmax Pro 5.2 (Molecular Devices). ELISA 
values were calculated with respect to the ELISA threshold limit of detection for each 
individual cytokine assay, which can be seen in Table 4-3. 
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Table 4-3. Threshold of detection for cytokines in ELISAs based on the cytokines in 
each figure. 
Figures Cytokines Threshold of 
detection in 
pg/mL 
Figure 5-1 IL-1β 310 
IL-6 160 
IL-12 390 
IL-17 470 
IL-23 390 
TGF-β 310 
Figure 5-2 IL-1β 310 
IL-6 160 
IL-12 390 
IL-17 470 
IL-23 390 
TGF-β 310 
Figure 5-3 IL-6 150 
IL-12 780 
IL-17 370 
TGF-β 310 
Figure 5-4 IL-6 150 
IL-12 780 
IL-17 370 
TGF-β 310 
Figure 5-5 IFNγ 310 
IL-4 310 
IL-10 625 
IL-17 500 
 
 
4.9 Mouse T Cell Phenotyping through intracellular flow cytometry 
After completing mouse spleen cell isolation on immunized mice, 100 µL of 
1.0x106 cells/well were added to 96-well tissue culture plates and then stimulated with 
OVA at 1 µg/mL or mock stimulated with 100 µL AIM V 10 % media alone. 
Restimulated cells were incubated at 37 °C in a 5 % CO2 incubator for 48 hours, at which 
point 20 µL of Monensin (BD Bioscience), a Golgi blocker, was pipetted into each well 
	 31	
for 8-12 hours. Cells were centrifuged at 500 x g for 4 minutes at RT, the supernatant was 
removed by flicking the plates then 200 µL flow cytometry buffer (FCM Buffer; FA 
COLA or PBSG; 1.5 g Sodium Azide and 10.0 g Gelatin into 5 L PBS pH 7.3) was added 
to wash the cells. The cells were centrifuged 500 x g for 4 minutes at RT and this wash 
was repeated twice. A volume of 100 µL of Fix/Perm Solution (BD Bioscience) was 
added to each well and plates were placed at 4 °C for a minimum of 30 minutes to 
permeablize the splenocytes. Cells were centrifuged at 500 x g for 4 minutes at RT and 
washed twice with Perm Wash (BD Bioscience). Supernatants were removed by flicking, 
then 10 µL of pre-diluted antibody (seen in Table 4-3) was added to each well and the 
plates were nutated and placed in the dark at RT for 10 minutes. Along with the cocktail 
stains used in this study, single, fluorochrome minus one (FMO), isotype, negative and 
positive control stains were used in this analysis and were added to wells at the same time 
as the cocktail stains. This study used 3 different cocktails to observe different T cells or 
mixed responses, the cocktails can be seen in Table 4-4 and individual antibodies in 
Table 4-5. After 10 minutes in the dark, cells were washed with 200 µL of Perm Wash 
and centrifuged at 500 x g for 4 minutes at RT and resuspended in 200 µL FCM buffer. 
Cells were measured on FacsCalibur (BD Biosciences Bio-Rad Laboratories) and 
CellQuestPro by acquiring 100,000 cells/sample. All data from FCM was analyzed on 
Kaluza (Beckman Coulter Life Sciences) and Graphpad prism with an example of the 
gating strategy shown in Figure 4-1. 
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Table 4-4. Flow cytometry fluorochrome cocktails. All Antibodies were Rat, anti-
mouse antibodies directly conjugated to fluorochromes (BD Pharmingen). 
Cocktail *Fluorochrome conjugated antibodies  
Cocktail 1 (C1) CD4-Cy5.5, IL-4-Alexa Fluor 647, IL-17-PE and 
IFNγ-FITC 
Cocktail 2 (C2) CD4-Cy5.5, IL-17-PE and Foxp3-Alexa Fluor 647 
Cocktail 3 (C3) CD4-Cy5.5, CD8-PE and IFNγ-FITC 
* All fluorochrome conjugated antibodies were purchased from BD Pharmingen. 
 
 
Table 4-5. Antibody fluorochrome chart for intracellular FCM performed on mouse 
spleen cells from immunization study (BD Pharmingen). Concentrations were made 
from stock to be administered per well or sample. 
Antibodies 
specific for: 
Fluorescence 
Channel 
Name Isotype Concentration 
of antibodies 
used per well 
CD4 FL3 PerCP-Cy™5.5 Rat 
Anti-Mouse CD4 Clone  
RM4-5 
Rat (DA) 
IgG2a, κ 
0.0625 µg/well 
CD8 FL2 PE Rat Anti-Mouse 
CD8b.2 Clone 53-5.8 
Rat (LOU) 
IgG1, κ 
0.25 µg/well 
Foxp3 FL4 Alexa Fluor® 647 Rat 
Anti-mouse Foxp3 
Clone MF23  
Rat IgG2a, κ 0.25 µg/well 
IL-4 FL4 APC Rat Anti-Mouse 
IL-4 Clone 11B11 
Rat IgG1 0.25 µg/well 
IL-17 FL2 PE Rat Anti-Mouse IL-
17A ClonTC11-18H10  
Rat IgG1 , κ 0.25 µg/well 
IFNγ FL1 FITC Rat Anti-Mouse 
IFNγ Clone XMG1.2  
Rat IgG1, κ 0.25 µg/well 
	 33	
 
 
Figure 4-1. Intracellular FCM gating strategy example of cocktail 1. FCM was used 
to identify quantities of different T cell subsets within a spleen cell population from 
immunized BALB/c after a 48 hour incubation with OVA. A portrays the live primary 
splenocyte gating from total population where cells are presented as side scatter (SSC) 
representing cell granularity and forward scatter (FSC) representing the size of cells. B 
portrays the gating of CD4+ cells from within the splenocyte gate. C portrays gating of 
intracellular cytokines i: IL-4, ii: IL-17 and iii IFNγ with the CD4+ gate. D gating was 
used to identify any CD4+ cells that may be producing multiple cytokines, which may 
give evidence of a mixed response or mixed T cell subset (i.e. Th1/Th17) i: CD4+ IL-17 
and IL-4 and ii: CD4+ IL-17 and IFNγ, these results are based on the CD4 gate. 	
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4.9.1 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism software (GraphPad 
Software, San Diego, CA, USA). Differences in the ELISA cytokine production were 
identified using a non-parametric Kruskal-Wallis ANOVA test where Dunn’s multiple 
comparisons test was used post-hoc to identify statistically significant differences in 
cytokine production (Figure 5-1, 5-2, 5-3, 5-4 and 5-5 in the results section). Differences 
in the FCM cytokine expression from CD4+ and CD8+ T cells were identified using a 
non-parametric Kruskal-Wallis ANOVA test where Dunn’s multiple comparisons test 
was used post-hoc to identify significant differences in OVA restimulated splenocytes 
expressing cytokine production as well as a Wilcoxon method t test between OVA 
restimulated and unstimulated (media) splenocytes within the immunization group 
(Figure 5-6 and 5-7 in the results section). Differences were presented with an asteryx (*) 
or through a letter system where all groups with the same letter are not significant from 
one another and those groups containing different letters are significant. Differences were 
considered statistically different if p value <0.05.   
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CHAPTER 5  Results 
5.1 Cytokine expression after in vitro stimulation of murine spleen cells with 
adjuvants 
We sought to identify which adjuvant(s) (Alum, CpG, Curdlan, Leptin, LPS and 
PCEP; Table 4-1) alone or in combination would stimulate production of IL-1β, IL-6, IL-
17, IL-23 and TGF-β cytokines that may promote Th17-type immunity or the cytokine 
IL-12, that may inhibit or decrease Th17 cell stability and differentiation in murine 
splenocytes. Multiple experiments were performed on different groups of adjuvants to 
determine optimal cytokine expression on treated mouse splenocytes in vitro.  
In figure 5-1, splenocytes from naïve mice were stimulated with varying doses (5, 
25, 50 and 125 µg/mL) of PCEP or media (mock-stimulation). ELISA cytokine analysis 
of IL-1β, IL-6, IL-12, IL-17, IL-23 and TGF-β expression (Figure 5-1) from mice 
splenocytes stimulated PCEP were performed on the supernatants after 48 hours. IL-1β 
(Figure 5-1A) was expressed at significantly higher levels by splenocytes cultured with 
media alone compared to the different PCEP concentrations, which suggests that PCEP 
inhibits IL-1β cytokine expression. Similar to IL-1β, IL-12 (Figure 5-1C) was expressed 
at higher levels in splenocytes with media alone compared to the PCEP treatments, which 
was significant with relation to PCEP 5 and 125 µg/mL. No concentrations of PCEP were 
able to significantly induce expression of cytokines, IL-6, IL-17, IL-23 and TGF-β, 
associated with Th17-type differentiation. Therefore, PCEP at the concentrations tested, 
does not induce significant expression of cytokines associated with a Th17-type cellular 
differentiation. 
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Figure 5-1. Titration of PCEP for optimal induction of IL-1β, IL-6, IL-12, IL-17, IL-
23 and TGF-β cytokine expression. Spleen were harvested from BALB/c mice (n = 5) 
and splenocytes isolated and incubated at 1.0 x 106 cells/well for in vitro incubation with 
PCEP at concentrations of 5, 25, 50 and 125 µg/mL. Supernatant was collected 48 hours 
after treatment and analyzed through ELISA with cytokine concetrations displayed as 
pg/mL. 
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Figure 5-2 displays an ELISA analysis of IL-1β, IL-6, IL-12, IL-17, IL-23 and 
TGF-β expression in mice splenocytes treated with CpG, PCEP, Alum, LPS, PCEP + 
CpG, PCEP + Alum, PCEP + LPS, PCEP + LPS + Alum, and PCEP + CpG + LPS or 
mock-stimulated cells for 48 hours. PCEP, PCEP + LPS + Alum and PCEP + CpG + 
LPS, did not induce significant IL-1β expression (Figure 5-2A) relative to splenocytes 
mock-stimulated with media. LPS and PCEP + LPS treatments induced significant IL-1β 
expression in splenocytes relative to splenocytes stimulated with PCEP, PCEP + LPS + 
Alum and PCEP + CpG + LPS. IL-6 (Figure 5-2B) was significantly expressed by 
splenocytes treated with PCEP + CpG and PCEP + CpG + LPS relative to splenocytes 
mock-stimulated with media as well as PCEP, PCEP + Alum and PCEP + LPS + Alum. 
Furthermore, PCEP + CpG + LPS treatment induced significant IL-6 expression relative 
to Alum. PCEP + CpG + LPS did not induce significant IL-6 expression relative to PCEP 
+ CpG suggesting that the triple combination was not more effective than the double 
adjuvant combination, PCEP + CpG relative to untreated cells in inducing IL-6 
expression in splenocytes (cells in media alone). In short, PCEP + CpG were just as 
effective in inducing IL-6 expression as PCEP + CpG + LPS. Adjuvants and adjuvant 
combinations that were able to significantly induce IL-12 (Figure 5-2C) expression in 
splenocytes were CpG, PCEP + CpG and PCEP + CpG + LPS relative to PCEP and 
PCEP + LPS + Alum. Although CpG was not able to induce significant expression of IL-
12 relative to media, PCEP + CpG or PCEP + LPS + Alum, it had a much higher 
concentration than all treatment groups, which suggests that CpG alone may be sufficient 
for inducing splenocytes to express IL-12 in vitro. IL-17 (Fig 5-2D) was not significantly 
expressed by cells treated with any of the adjuvants alone or in combination. However,  
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Figure 5-2. Expression of IL-1β, IL-6, IL-12, IL-17, IL-23 and TGF-β under single, 
double and triple adjuvant treatment conditions. Spleens were harvested from 
BALB/c mice (n = 5 minimum) and splenocytes isolated and incubated at 1.0 x 106 
cells/well for in vitro culture with CpG (5 µg/mL), PCEP (25 µg/mL), Alum, (40 µg/mL) 
LPS (5 µg/mL), PCEP + CpG (25 + 5 µg/mL, respectively), PCEP + Alum (25 + 40 
µg/mL, respectively), PCEP + LPS (25 + 5 µg/mL, respectively), PCEP + CpG + Alum 
(25 + 5 + 40 µg/mL, respectively) and PCEP + CpG + LPS (25 + 5 + 5 µg/mL, 
respectively). Supernatant was collected 48 hours after treatment and analyzed through 
ELISA displayed as pg/mL. 
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there were multiple high responders within the PCEP + CpG, PCEP + Alum, PCEP + 
LPS, PCEP + CpG + LPS and PCEP + LPS + Alum treatment groups. IL-23 and TGF-β 
(Figure 5-2E and 5-2F, respectively) were not significantly expressed by splenocytes 
from any of the treatment groups and there were very few individuals/samples responding 
to the different treatments. Therefore, all of the adjuvants and their combinations tested in 
this study did not induce cytokines associated with the development of a Th17-type of 
immune response.  
As the previous adjuvants did not induce a cytokine expression profile that 
promotes a Th17-type of immune responses, we added Curdlan, Leptin and their 
combinations because these two immunostimulants have been observed to induce signals 
for inducing Th17 cell differentiation through TLRs and syk-CARD9 [86, 93]. We also 
eliminated the IL-1β and IL-23 ELISAs as they only indirectly influence Th17 cell 
differentiation. 
Figure 5-3 displays ELISA analysis of murine splenocytes stimulated with CpG, 
PCEP, Leptin, Curdlan, PCEP + Leptin, PCEP + Curdlan, PCEP + CpG + Leptin, PCEP 
+ Curdlan + Leptin, CpG + Curdlan + Leptin as well as mock-stimulated for 48 hours and 
then IL-6, IL-12, IL-17 and TGF-β cytokines were quantified.  
IL-6 (Figure 5-3A) was significantly expressed by splenocytes stimulated with 
PCEP + CpG + Leptin relative to splenocytes in media. CpG, PCEP + CpG + Leptin and 
CpG + Curdlan + Leptin were able to induce splenocytes to express significant IL-6, 
relative to PCEP + Curdlan + Leptin. CpG and PCEP + CpG + Leptin also induced 
splenocytes to express significantly more IL-6 relative to PCEP, PCEP + Leptin, PCEP + 
Curdlan and Curdlan + Leptin.  
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IL-12 (Figure 5-3B) was significantly expressed by splenocytes treated with CpG 
and CpG + Curdlan + Leptin relative to splenocytes in media. CpG and CpG + Curdlan + 
Leptin were also able to induce splenocytes to significantly express IL-12 relative to 
splenocytes stimulated with PCEP, PCEP + Leptin, PCEP + CpG + Leptin, PCEP + 
Curdlan and PCEP + Curdlan + Leptin. Splenocytes treated with Curdlan were also able 
to induce IL-12 expression relative to PCEP and PCEP + Leptin. CpG + Curdlan + 
Leptin was not able to induce splenocytes to significantly express IL-12 relative to CpG, 
concluding that CpG alone is just as effective as the triple combination in inducing IL-12 
expression. IL-12 has the ability to switch from Th17 cells into Th1 or Th1/Th17 cells so 
an adjuvant combination that does not induced IL-12 secretion may be desirable when 
inducing a Th17-type immune response.  
IL-17 (Figure 5-3C) was significantly expressed by splenocytes treated with 
Curdlan + Leptin as well as PCEP + Curdlan + Leptin relative to splenocytes in media 
alone. Curdlan + Leptin and PCEP + Curdlan + Leptin were also able to induce 
significant IL-17 expression relative to splenocytes stimulated with CpG, PCEP + CpG + 
Leptin, Curdlan, PCEP + Curdlan and CpG + Curdlan + Leptin. The triple combination, 
PCEP + Curdlan + Leptin, did not induce significant expression of IL-17 relative to 
Curdlan + Leptin, indicating that the double adjuvant combination is just as effective in 
IL-17 expression as the triple combination.  
Lastly, Curdlan, PCEP + Curdlan and CpG + Curdlan + Leptin were able to 
induce splenocytes to significantly induce expression of TGF-β (Figure 5-3D) relative to 
media alone. Curdlan and PCEP + Curdlan treated splenocytes were also able to induce 
TGF-β expression relative to PCEP + Leptin and PCEP + CpG + Leptin. CpG + Curdlan 
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+ Leptin was also able to induce significant TGF-β expression relative to CpG, PCEP, 
Leptin, PCEP + Leptin and PCEP + CpG + Leptin.  
It was expected that IL-6 and TGF-β would be expressed by similar adjuvants that 
promote Th17 cell differentiation characteristics. However, we observed that IL-6 and 
IL-12 were both produced by CpG alone or in combination with other adjuvants. This is 
undesirable, as IL-12 is known to promote a switch in differentiation from Th17 to Th1. 
Curdlan + Leptin in the presence or absence of PCEP were shown to induce expression of 
IL-17 although no adjuvant combination induced expression of both IL-6 and TGF-β. 
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Figure 5-3. Expression of IL-6, IL-12, IL-17 and TGF-β under single, double and 
triple adjuvant treatment conditions. Spleen were harvested from BALB/c mice (n = 
6) and splenocytes isolated and incubated at 1.0 x 106 cells/well for in vitro treatment 
with CpG (5 µg/mL), PCEP (25 µg/mL), Leptin (1 µg/mL), PCEP + Leptin (25 + 1 
µg/mL, respectively), PCEP + CpG + Leptin (25 + 5 + 1 µg/mL, respectively), Curdlan 
(1 µg/mL), PCEP + Curdlan (25 + 1 µg/mL, respectively), Curdlan + Leptin (1 + 1 
µg/mL, respectively), PCEP + Curdlan + Leptin (25 + 1 + 1 µg/mL, respectively), CpG + 
Curdlan + Leptin (5 + 1 + 1 µg/mL, respectively). Supernatant was collected 48 hours 
after treatment and analyzed through ELISA displayed as pg/mL. 
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5.2 Local cytokine production in a murine model after ex vivo stimulation of 
intramuscular injected adjuvants  
Next, using adjuvants in Objective 1, we investigated what cytokines would be 
locally expressed in murine muscle tissues after injection with CpG, PCEP, LPS, Alum, 
Curdlan, Leptin, PCEP + CpG, PCEP + LPS, PCEP + Alum, PCEP + Curdlan, PCEP + 
Curdlan + Leptin, CpG + Curdlan + Leptin or PBS (See Table 4-1 for concentrations). 
IL-6 (Figure 5-4A) expression was significantly induced at the site of injection by 
PCEP, CpG, PCEP + CpG and PCEP + LPS injections relative to injections of PBS 
alone. IL-6 expression was also significantly induced by the PCEP, CpG, PCEP + CpG 
and PCEP + LPS injections relative to Curdlan, Leptin and Curdlan + Leptin. PCEP + 
CpG were not able to induce significant IL-6 expression at the site of injection relative to 
the single PCEP and CpG adjuvant injections, showing us that single adjuvants PCEP and 
CpG are just as effective as the double combination at inducing IL-6 expression.  
IL-12 (Figure 5-4B) expression was significantly induced at the site of injection 
with Curdlan + Leptin relative to the PBS injection group. IL-12 was also significantly 
expressed by Curdlan + Leptin relative to the PCEP, LPS, PCEP + LPS, Alum and PCEP 
+ Curdlan injection groups which may mean these adjuvants may promote Th1-type cell 
differentiation over Th17-type cell differentiation. 
IL-17 (Figure 5-4C) expression was induced by an injection of Curdlan + Leptin 
relative to the PBS injection as well as to the CpG, PCEP + CpG, LPS, PCEP + LPS, 
Alum and PCEP + Alum injection groups. Injections of Curdlan, PCEP + Curdlan, 
Leptin, PCEP + Curdlan + Leptin and CpG + Curdlan + Leptin were able to induce 
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significant IL-17 expression at the site of injection relative to CpG, LPS, PCEP + LPS 
and Alum.  
Lastly, TGF-β (Figure 5-4D) expression was significantly induced at the site of 
injection in response to Curdlan + Leptin relative to the mice injected with PBS as well 
as LPS.  
As with the in vitro data, we observed that the combination of Curdlan + Leptin 
was able to induce significant expression of IL-17 at the site of injection, which may 
indicate Th17 cell differentiation but due to the short time period it is likely that IL-17 
expression represents activation of effector Th17 or other cells like 
monocytes/macrophages, which also have the ability to express IL-17 and are present in 
the muscle [148]. From here, we moved onto an immunization study to determine if there 
was an antigen-specific Th17-type of immune response using adjuvants previously 
observed to promote IL-17 expression. 
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Figure 5-4. Expression of IL-6, IL-12, IL-17 and TGF-β at the site of injection. 
BALB/c mice (n = 6) were injected with PBS alone and adjuvants diluted in PBS: PCEP 
(50 µg/mL), CpG (10 µg/mL), LPS (10 µg/mL), Alum (40 µg/mL), Curdlan (10 µg/mL), 
Leptin (10 µg/mL), PCEP + CpG (50 + 10 µg/mL, respectively), PCEP + LPS (50 + 10 
µg/mL, respectively), PCEP + Alum (50 + 40 µg/mL, respectively), PCEP + Curdlan (50 
+ 10 µg/mL, respectively), Curdlan + Leptin (10 + 10 µg/mL, respectively), PCEP + 
Curdlan + Leptin (50 + 10 + 10 µg/mL, respectively) and CpG + Curdlan + Leptin (10 + 
10 + 10 µg/mL, respectively). Muscle tissue was excised 48 hours after injection and 
subjected to ELISA analysis to identify cytokine expression at the site of injection 
displayed as pg/mL.  
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5.3 Murine cytokine expression post-immunization with Ovalbumin and 
single or combinational adjuvants  
After quantifying cytokine expression in vitro and at the site of injection, we 
concluded that Curdlan + Leptin and PCEP + Curdlan + Leptin were able to induce IL-17 
expression in vitro and Curdlan + Leptin was able to induce IL-17 expression at the site 
of injection. Thus, we decided to use PCEP, Curdlan, Leptin alone and in combinations in 
our immunization study to assess Th17-type cell differentiation.  
We immunized mice with vaccines formulated with OVA alone, PCEP + OVA, 
Curdlan + OVA, Leptin + OVA, PCEP + Curdlan + OVA, Curdlan + Leptin + OVA or 
left mice unimmunized (naïve). Mice received identical booster immunizations on Day 
21 and we harvested spleens on Day 35. ELISA results from the splenocytes, which were 
mock-stimulated or restimulated with OVA from all immunization groups are shown in 
Figure 5-5 for induction of IFNγ, IL-4, IL-10 and IL-17, which are related to the presence 
of Th1, Th2, Tregs and Th17 cells, respectively. Flow cytometry data from splenocytes, 
mock-stimulated or restimulated with OVA in Figure 5-6, shows the frequency of CD4+ 
T cells that express IFNγ, IL-4, IL-10 or IL-17, indicative of Th1, Th2, Tregs and Th17-
type cell subsets, respectively. In Figure 5-7, splenocytes were gated for CD4+ or CD8+ 
cells expressing IFNγ to identify whether IFNγ was produced primarily from Th1 cells or 
CTLs. 
Cytokine ELISA results from the immunization trial showed that no vaccine, even 
with adjuvant combinations, induced significant OVA-specific induction of IFNγ (Figure 
5-5A), IL-4 (Figure 5-5B) or IL-10 (Figure 5-5C). IL-17 (Figure 5-5D) expression was  
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Figure 5-5. Expression of IFNγ, IL-4 IL-10 and IL-17 after OVA restimulation in 
immunization groups. BALB/c spleen were harvested (n= 8) and splenocytes isolated 
from all mice, naïve and immunized with OVA and OVA + Adjuvants: Naïve (no 
immunization), PBS + OVA (10 µg/mL), PCEP + OVA (50 + 10 µg/mL, respectively), 
Curdlan + OVA (10 + 10 µg/mL, respectively), Leptin + OVA (10 + 10 µg/mL, 
respectively), PCEP + Curdlan + OVA (50 + 10 + 10 µg/mL, respectively) and Curdlan + 
Leptin + OVA (10 + 10 + 10 µg/mL, respectively). Cells from these mice were mock-
stimulated with media alone as well as restimulated with OVA (1 µg/mL), incubated at 
1.0 x 106 cells/well for 48 hours and analyzed through ELISA in pg/mL. OVA-specific 
titres were calculated by subtracting titres from unstimulated splenocytes from the OVA 
restimulated splenocytes.  
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significantly induced in splenocytes from mice immunized with PCEP + OVA relative to 
the mice immunized with Curdlan + OVA, although it was insignificant with respect to 
the OVA immunization group presumably due to the highly variable responses.  
Using flow cytometry analysis, we quantified the percentage of CD4+ splenocytes 
that expressed IFNγ, IL-4, IL-17 or Foxp3 in response to OVA restimulation (Figure 5-
6). Neither IFNγ nor IL-4 (Figure 5-6A and Figure 5-6B, respectively) were expressed by 
CD4+ splenocytes in response to OVA from any of the vaccine formulations.  
Immunization with PCEP + OVA induced a significant increase in the frequency 
of OVA-specific CD4+IL17+ splenocytes (Figure 5-6C) relative to mice immunized with 
OVA alone, and PCEP + Curdlan + OVA. Immunization with Curdlan + Leptin + OVA 
induced significantly more OVA-specific CD4+IL17+ splenocytes relative to mice 
immunized with PCEP + Curdlan + OVA. Splenocytes from mice immunized with PCEP 
+ OVA and Curdlan + Leptin + OVA restimulated with OVA for 48 hours also had 
significant expression of IL-17 on CD4+ T cells relative to the unstimulated splenocytes.  
The frequency of CD4+ splenocytes expressing Foxp3 (Figure 5-6D) showed no 
significant difference between the immunization groups restimulated with OVA. 
However, there was a significance difference between the unstimulated and OVA 
restimulated splenocytes from the Curdlan + OVA, Leptin + OVA and Curdlan + Leptin 
+ OVA immunization groups. Mice immunized with Leptin + OVA showed a significant 
increase in the frequency of CD4+ splenocytes expressing both IL-17 & IFNγ (Figure 5-
6E) relative to Curdlan + OVA and PCEP + Curdlan + OVA immunization groups. Mice 
immunized with OVA and Leptin + OVA showed a significantly higher frequency of 
CD4+ splenocytes expressing both IL-17 & IL-4 (Figure 5-6F) relative to Curdlan + OVA 
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immunization group. Mice immunized with Curdlan + Leptin + OVA showed a 
significant increase in the frequency of OVA-specific CD4+IL-17+ T cells, CD4+Foxp3+ 
T cells and CD4+IL-17+Foxp3+ T cells (Figure 5-6 C, D and G). 
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Figure 5-6. Expression of IFNγ, IL-4, IL-17, Foxp3, IL-17 & IFNγ IL-17 & IL-4 and 
IL-17 & Foxp3 on CD4+ cells of immunized mice. BALB/c were immunized and 
boosted with 50 µL (25 µL per leg) of OVA or OVA + Adjuvant as: PBS + OVA (10 
µg/mL), PCEP + OVA (50 + 10 µg/mL, respectively), Curdlan + OVA (10 + 10 µg/mL, 
respectively), Leptin + OVA (10 + 10 µg/mL, respectively), PCEP + Curdlan + OVA (50 
+ 10 + 10 µg/mL, respectively) and Curdlan + Leptin + OVA (10 + 10 + 10 µg/mL, 
respectively). Spleen cells were isolated and mock-stimulated with media or restimulated 
with OVA (1 µg/mL) and incubated for 48 hours. Splenocytes were then stained with 
antibodies for CD4+ markers as well as A) IFNγ B) IL-4 C) IL-17 D) Foxp3 E) IL-17 & 
IFNγ and F) IL-17 & IL-4 G) IL-17 & Foxp3 markers to determine the percent of 
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cytokine producing CD4 cells, associated with Th1, Th2, Th17 and Tregs, respectively as 
well as analyzing for double positive cells, indicating a mixed response. 
 
 Cytokine ELISA analysis indicated that PCEP + OVA immunization group 
produced significant IL-17 than did the splenocytes from mice immunized with Curdlan 
+ OVA. Through FCM we observed that the PCEP + OVA immunization group 
expressed significantly more IL-17 relative to the OVA formulation group. OVA-specific 
CD4+ IL-17 T cells were more abundant in the mice immunized with PCEP + OVA and 
Curdlan + Leptin + OVA immunization groups which suggests that these vaccines 
induced antigen-specific Th17-type cell differentiation. 
Figure 5-7 displays the percent of OVA-induced CD4+ and CD8+ splenocytes 
expressing IFNγ (Figure 5-7A and 5-7B, respectively) 35 days post immunization, 
which indicates OVA-specific Th1 cells or CTLs post-immunization. Neither CD4+ nor 
CD8+ cells showed a significant increase in the frequency of OVA-specific IFNγ 
producing cells. 
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Figure 5-7. Expression IFNγ on CD4+ and CD8+ cells of immunized mice. BALB/c 
were immunized and boosted with 50 µL (25 µL per leg) of OVA or OVA + Adjuvant as: 
PBS + OVA (10 µg/mL), PCEP + OVA (50 + 10 µg/mL, respectively), Curdlan + OVA 
(10 + 10 µg/mL, respectively), Leptin + OVA (10 + 10 µg/mL, respectively), PCEP + 
Curdlan + OVA (50 + 10 + 10 µg/mL, respectively) and Curdlan + Leptin + OVA (10 + 
10 + 10 µg/mL, respectively). Spleen cells were isolated and mock-stimulated with media 
or restimulated with OVA (1 µg/mL) and incubated for 48 hours. Splenocytes were then 
stained with antibodies for A) CD4+ and B) CD8+ markers as well as IFNγ markers to 
determine the quantity of cytokine producing CD4 and CD8 T cells.   
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CHAPTER 6  DISCUSSION 
6.1 Discussion 
Th17 responses are of much importance as they promote protection against fungal 
and bacterial infections as well as aid in cancer immunity. Therefore, it is important to 
study adjuvants or other tools in immunology to identify a means to promote a safe and 
effective Th17-type response. The mechanisms of action by which adjuvants direct an 
immune response towards one type of immune response or another type is not always 
known but induction of a specific cytokine environment may be one mechanism to 
induce Th17-type responses. As stated previously, Th17 cells express IL-17 as well as 
IL-21 and IL-22 cytokines [7, 132, 141]. Th17 cells differentiate from naïve T cells under 
a combined IL-6 and TGF-β cytokine environment [7, 132, 141]. IL-1β and IL-23 are 
important for the stability and upregulation of Th17 cell differentiation, and may be 
beneficial when seeking to make a vaccine to induce Th17 type immunity [7, 132, 141]. 
There is evidence that Th17 cells are highly plastic and the current research suggests that 
IL-12 in the environment can cause a switch in differentiation from a Th17 cell to a Th1 
cell or a mixed cell Th1/Th17 and therefore IL-12 in the cytokine environment may also 
be not preferred when it is desirable to induce a Th17 type immune response to a vaccine 
[113, 135, 141]. My hypothesis was that we could identify PCEP or another adjuvant and 
their combinations would promote a Th17-type of response to a vaccine antigen. To test 
this hypothesis, we studied the effect that select adjuvants had on induction of IL-1β, IL-
6, IL-12, IL-17, IL-23 and TGF-β in murine splenocytes in vitro and how they impacted 
the local cytokine environment when injected into muscle tissue. We also quantified 
IFNγ, IL-4, IL-10/Foxp3 and IL-17 production in response to immunization to assess 
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whether these adjuvants induced a Th1, Th2, Tregs, Th17 or mixed type immune 
response. We anticipated that a consistent cytokine profile would be induced by these 
adjuvants across tissues and in response to the vaccine.  
Through in vitro studies (Figure 5-1, 5-2 and 5-3) we observed splenocytes 
cultured with adjuvants promoted different significant cytokine expression relative to 
splenocytes cultured in media alone. We were encouraged that PCEP alone did not 
promote IL-1β or IL-12 but promoted inhibition of IL-12 expression from splenocytes 
stimulated with PCEP or combinations with PCEP in these studies. IL-12 expression 
seemed to be present in these unstimulated splenocytes in vitro. However, it did not 
promote expression of IL-6, TGF-β or IL-17 either. This was inconsistent with findings 
from Awate et al (2012) where the IL-6 gene was observed to be expressed in response to 
PCEP but was consistent with the findings that IL-12 gene expression was produced from 
CpG but not PCEP [68]. In this same study, the IL-17 gene expression was increased at 
96 hours; this may indicate that we needed to try a much longer time point to observe IL-
17 expression by PCEP in vitro.  
When we expanded our analysis to include the immunostimulants, Curdlan and 
Leptin, we observed that Curdlan +/- PCEP in vitro induced expression of splenocytes 
TGF-β and Curdlan + Leptin+/- PCEP induced expression of IL-17 which we speculated 
could mean that Th17 cells were being differentiated under these conditions. There has 
not been a lot of research behind IL-17 expression but there is evidence that innate αβ T 
cells, γδ T cells, NK cells and myeloid cells may produce IL-17A [149-154], while T 
helper cells are responsible for the production of IL-17F [7, 132]. So, because we did not 
directly investigate what cells were responsible for the expression of IL-17, we can only 
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speculate what cells may have been responsible during this in vitro study. Others have 
shown that neutrophils from cultured murine lungs produced IL-17A in response to 
Dectin-1 signalling so it is possible that Curdlan signalling through Dectin-1 receptor 
induced expression of IL-17 from spleen neutrophils [155]. However, because Dectin-1 
receptor is also present on macrophages/monocytes, and DCs, Curdlan could have 
activated these innate immune cells, which in turn induced activation of memory Th17 
cells [86, 88, 156-158]. Human DCs stimulated by Dectin-1 agonists have been shown to 
induce secretion of IL-1β, IL-6 and IL-23, with low levels of IL-12 which prime naïve 
CD4+ cells to differentiate into Th17 and Th1 cells [158]. Like Dectin-1 receptor, Leptin 
receptors are also present on neutrophils, monocytes, and lymphocytes but Leptin 
signalling may be critically required for Th1 or Th17 differentiation [101, 159]. Both IL-
6 and Leptin are able to induce RORγt, Th17’s master regulator, which could make it 
possible that Leptin is acting as /similar to IL-6 in facilitating Th17 cell development [93, 
160, 161]. Leptin induces functional and morphological changes in human dendritic cells 
(DCs), directing them towards Th1 priming and promoting DC survival [162]. Further, 
mouse CD4+ and CD8+ T lymphocytes express the Leptin receptor and respond to Leptin 
with promotion of T cell number and activation [163]. The Leptin receptor is highly 
expressed on the cell surface of human Tregs and acts as a negative signal for their 
proliferation [164]. Thus, Leptin may act on the murine splenic Th17 cells directly or 
indirectly through induced innate immune cell activation. Finally, PCEP was shown to 
induce robust secretion of IL-1β and IL-18 in murine splenic DCs as well as promote 
increased production of IFNγ from CD4+ and CD8+ T Cells [165]. Therefore we 
speculate that it is unlikely that PCEP triggered induction of IL-17 production from 
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CD4+ T cells in the spleen from naïve mice. Together Curdlan, Leptin and PCEP may 
have induced IL-17 production from effector Th17 type immune cells, from innate 
immune cells or they promoted Th17 type immune cell differentiation. 
Our ultimate goal was to use adjuvants in an immunization study to induce an 
antigen-specific Th17-type of immune response. Thus, we wanted to understand how 
these adjuvants impacted the local cytokine environment in the muscle in the period after 
injection. Again we predicted that the effect of the adjuvants on the muscle cells would 
show a similar pattern of induction of the local cytokine environment as was observed in 
splenocytes. Through a muscle tissue injection study, where adjuvants were injected 
without antigen (Figure 5-4), we observed which adjuvants were able to promote 
significant expression of cytokines in cells recruited to or already present at the site of 
injection. PCEP induced IL-6 expression at the site of injection and Curdlan + Leptin 
induced IL-12, IL-17 and TGF-β expression. Similar to the in vitro splenocyte 
stimulation, no injections were able to induce both IL-6 and TGF-β expression at the site 
of injection which others have shown is necessary for Th17 cell development [7, 132]. As 
we saw in the splenocyte culture in vitro studies, injection of Curdlan+/-Leptin+/- PCEP 
induced significant IL-17 expression after injection into muscle and therefore must be 
impacting induction of innate immune cell-mediated expression of IL-17 or they are 
activating local effector T cell production of IL-17.  
It is known that IL-6 and IL-12 can be produced by DCs through the activation of 
TLR9, MyD88 and TRAF6 by CpG [40], therefore it is likely that any combination of 
adjuvants that include CpG will produce both IL-6 and IL-12. IL-6 promotes the cell 
differentiation switch from Treg to Th17, while IL-12 promotes the cell differentiation 
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switch from Treg to Th1 or Th17 to Th1 [113, 166]. Thus, we predict that it would be 
most beneficial to identify an adjuvant able to induce expression of IL-6 and TGF-β 
without expression of IL-12. All conditions including CpG in this in vitro study showed 
some production of IL-12. So, we speculated that they would not be desirable as Th17 
cell -inducing adjuvants. Therefore, we removed the adjuvants promoting IL-12 
expression from the immunization studies as well as the adjuvants not able to induce IL-
17 characteristics. This elimination left us primarily with PCEP, Curdlan and Leptin to 
continue on to our immunization study. Because the quantification of cytokines through 
an ELISA does not allow us to determine which cells in the spleen are expressing 
cytokines, we preformed both ELISA and FCM to determine if the cytokines being 
quantified in the ELISAs were being produced from CD4+ T helper cells.  
When we vaccinated mice i.m. with OVA + PCEP, Curdlan, Leptin and 
combinations thereof, the resultant antigen-specific immune response was distinct from 
that which we observed in vitro and in vivo in the acute period after injection. We 
specifically quantified the frequency of CD4+ T cells expressing IL-4, Foxp3, IL-17 or 
IFNγ as a measure of Th2-type, Treg-type, Th17-type or Th1-type cell OVA-specific 
immunity, respectively. CD4+ T cells expressing IL-17 were produced as a result of an 
antigen-specific immune response from the PCEP + OVA and Curdlan + Leptin + OVA 
immunization groups. The Curdlan + Leptin + OVA immunization group also produced 
Treg cells (CD4+Foxp3 expressing cells) and a small but significant mixed response, 
Th17/Treg (CD4+IL-17+Foxp3+ expressing cells).  
These data indicate that we may be observing a mixed type of cell under these 
conditions but because of the low CD4+ cell percentages it is unlikely that we are seeing a 
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mixed-type of immune response but that rather both Th17 cells and Tregs are both being 
produced in response to the antigen, OVA. Others have shown that it is possible to have a 
Th17 or Treg cell development if TGF-β is induced either alone or in combination with 
induction of IL-6 [113, 132]. It is also theorized that it is necessary to have a balanced 
ratio of Th17 to Treg cells to regulate a Th17-type of immune response to avoid 
promotion of an autoimmune disease in a largely increased Th17 cell environment [136, 
137, 167].  
Curdlan + Lepton were able to consistently promote significant IL-17 expression 
in vitro, in an adjuvant injection study and in an immunization study through an OVA-
specific response. Both of these immunostimulants were added to this project as 
adjuvants because of their ability to promote the differentiation of Th17 cells. However, 
throughout this project we were not able to induce cytokine expression of IL-6 and TGF- 
β from any similar conditions in vitro or ex vivo. This portrays that we may not be able to 
predict immunization adjuvants through in vitro and ex vivo immunostimulants. Curdlan 
induces DCs to produce Th17 developmental characteristics: IL-6 and IL-23 and Leptin 
are able to signal Th17 regulators: RORγt and STAT3 [85, 88, 93]. Because we observed 
CD4+Foxp3+ cells production in response to Curdlan + OVA, Leptin + OVA and Curdlan 
+ Leptin + OVA immunizations, we can speculate that Tregs are being differentiated. 
Tregs produce TGF-β, needed for Th17 cell development and one study suggested that 
adding Curdlan to a CD4+Foxp3+ environment produced an accumulation of CD4+IL-
17+Foxp3+ (double positive) cells [85]. This same study found that adding Curdlan to a 
naïve mouse cell culture also induced CD4+ cells to express IL-17 [85]. Therefore, under 
the Curdlan + Leptin + OVA immunization conditions, we can speculate that because of 
	 59	
the presence of Tregs and other stromal cells, which produce TGF-β, and the addition of 
Curdlan and Leptin, both of which induce IL-6 production, we have attained suitable 
conditions for the development of Th17 cells.  
Although we have attained optimal conditions for promoting a Th17-type of 
immune response, more research must be done. The murine model is not an ideal model 
for veterinary or human vaccine development, but they are rather a stepping-stone to 
finding future adjuvant and vaccine candidates. It would be ideal to test these findings on 
a different animal model, while also conducting dose titrations, safety and protection 
studies of the adjuvants. It would also be beneficial to consider antigens of diseases that 
may be mediated by a Th17-type of response, as OVA may not indicate proper antigen-
specific responses. Therefore, there are many variables that will need to be reviewed for 
future studies. 
 
 6.2  General Conclusions 
We conclude that significant IL-17 expression can be induced in murine 
splenocytes stimulated with Curdlan + Leptin and PCEP + Curdlan + Leptin, and in 
muscle tissue injected with Curdlan + Leptin +/-PCEP. Immunization with PCEP + OVA 
and Curdlan + Leptin + OVA showed induction of Th17-type immunity. Mice 
immunized with Curdlan and Leptin alone or combined showed induction of Foxp3+IL-
17+CD4+ T cells. Further studies are needed to assess whether Foxp3+IL-17+CD4+T cells 
lead to the development of protective Th17-type of immunity against pathogens or 
autoimmune diseases.  
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Overall, the Curdlan + Leptin combination is able to induce a Th17-type of 
immune response in vitro and ex vivo. Curdlan + Leptin + OVA and PCEP + OVA are 
able to induce an antigen-specific Th17-type of immune response. These results portray 
potential safe and effective vaccine adjuvant abilities. However, it would be beneficial to 
conduct more studies with these adjuvants to determine their protective abilities in 
immunizations for both human and veterinary vaccines. 
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